Lecanemab Injection.乐意保（仑卡奈单抗注射液）

Effects and Benefits:
Lencanezumab is used to treat mild cognitive impairment caused by Alzheimer’s disease and mild dementia due to Alzheimer’s disease.
Dosage and Administration:
Dilution Instructions: Dilute in 250 mL of 0.9% Sodium Chloride Injection before administration. Use aseptic technique when preparing the Lencanezumab diluent for intravenous infusion. Calculate the required dose (mg), total volume (mL), and number of bottles of Lencanezumab solution based on the patient’s actual weight and recommended dose (10 mg/kg). Each vial contains 100 mg/mL of Lencanezumab. Whenever the solution and container permit, the Lencanezumab solution should be visually inspected for particulate matter and discoloration before administration. Check to confirm that the Lencanezumab solution is a clear to opalescent, colorless to pale yellow liquid. Do not use if there are opaque particles, discoloration, or other foreign particles. Remove the flip cap from the vial. Insert the sterile syringe needle into the vial through the center of the rubber stopper. Remove the required volume of lencanezumab from the vial and add to an infusion container containing 250 mL of 0.9% Sodium Chloride Injection. Each vial is for single use only. Discard any unused portion. Gently invert the infusion container containing the lencanezumab diluted solution to mix thoroughly. Do not shake. After dilution, immediate use is recommended. If not administered immediately, refrigerate lencanezumab at 2-8°C for up to 4 hours, or at room temperature up to 30°C for up to 4 hours. Do not freeze. Instructions for Use: Before administration, visually inspect the lencanezumab diluted solution for particles or discoloration. If discolored, or if unclear or foreign matter is seen, do not use. Allow the lencanezumab diluted solution to warm to room temperature before infusion. Infuse the full volume of the lencanezumab diluted solution intravenously through an intravenous line containing a terminal low protein binding infusion line filter (pore size 0.2 μm) for approximately 1 hour. Flush the infusion line to ensure that all the lencanezumab has been used. Monitor for any signs or symptoms of infusion-related reactions. The infusion rate may be reduced or stopped, and appropriate treatment may be given as clinically indicated. Pre-infusion prophylaxis with antihistamines, nonsteroidal anti-inflammatory drugs, or corticosteroids may be considered for subsequent dosing.
Adverse Reactions:
Lencanezumab, as a drug for the treatment of mild cognitive impairment caused by Alzheimer’s disease and mild dementia due to Alzheimer’s disease, may cause some discomfort, but these reactions usually resolve on their own over time. The following are some common reactions that may occur: Infusion-related reactions: When receiving lencanezumab treatment, some patients may experience mild infusion-related discomfort, such as fever, chills, body aches, feeling shaking, joint pain, etc. These reactions are usually most common during the first infusion and are mostly mild to moderate. Headache: Some patients may experience headaches during treatment, but this usually does not affect daily life. Nausea and vomiting: Some patients may feel nauseous or vomit during treatment, but these symptoms can usually be managed by adjusting the treatment plan. ARIA (Amyloid-Associated Imaging Abnormality): This is an imaging change that may manifest as cerebral edema or microbleeds. In most cases, ARIA is asymptomatic. Other rare reactions: including rash, dyspnea, etc. If these symptoms occur, please contact your doctor in time. Please note that these reactions are not experienced by every patient, and most reactions are temporary. If you have any doubts or concerns, or experience any discomfort during treatment, it is recommended to communicate with a medical professional in a timely manner.
Drug contraindications:
This product is contraindicated if you are allergic to it